Clinical Trials
A Multicenter Phase 1 Study to Determine the Maximum Tolerated Dose/ Maximum Feasible Dose, Safety, and Efficacy of Single Dose Rhenium-186 NanoLiposome (186RNL) Administered via Intraventricular Catheter for Leptomeningeal Metastases (CTMS# 21-0138)
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Andrew Brenner MD
For more information about this study
View DetailsAbout This Study
This is an open-label, multicenter, Phase 1 dose-escalation study to establish the safety and tolerability of a single dose of 186RNL by the intraventricular route (via intraventricular catheter) and to identify a maximum tolerated dose (MTD) and/or maximum feasible dose (MFD).